All FDA-approved EMA-approved PMDA-approved
Target Card Uniprot Example: P23975

dexamethasone phosphate 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
	3920	2392-39-4

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: dexamethasone phosphate dexamethasone sodium phosphate decadron dexamethasone phosphoric acid	An anti-inflammatory 9-fluoro-glucocorticoid Molecular weight: 472.45 Formula: C22H30FO8P CLOGP: 0.32 LIPINSKI: 0 HAC: 8 HDO: 4 TPSA: 141.36 ALOGS: -2.21 ROTB: 4 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Drug dosage:

None

ADMET properties:

Property	Value	Reference
S (Water solubility)	0.08 mg/mL	Bocci G, Oprea TI, Benet LZ

Approvals:

Date	Agency	Company	Orphan
Sept. 2, 1959	FDA	MERCK

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Neutrophil count decreased	248.36	15.61	150	12713	56256	63419903
Febrile neutropenia	205.62	15.61	179	12684	118270	63357889
Platelet count decreased	144.63	15.61	146	12717	115976	63360183
Myelosuppression	122.53	15.61	70	12793	23633	63452526
Interstitial lung disease	116.30	15.61	98	12765	61810	63414349
White blood cell count decreased	101.98	15.61	133	12730	138971	63337188
Bone marrow failure	101.49	15.61	67	12796	29223	63446936
Hepatic function abnormal	87.16	15.61	67	12796	37075	63439084
Anaphylactic shock	84.15	15.61	55	12808	23578	63452581
Neutropenia	77.33	15.61	132	12731	174873	63301286
Anaemia	65.39	15.61	167	12696	293263	63182896
Pneumocystis jirovecii pneumonia	61.77	15.61	40	12823	16874	63459285
Neuropathy peripheral	60.03	15.61	93	12770	113574	63362585
Pyrexia	53.32	15.61	212	12651	470266	63005893
Acute lymphocytic leukaemia recurrent	52.18	15.61	19	12844	2250	63473909
Colony stimulating factor therapy	50.46	15.61	12	12851	315	63475844
Joint swelling	48.60	15.61	5	12858	327661	63148498
Aortitis	44.36	15.61	14	12849	1073	63475086
Thrombocytopenia	42.20	15.61	94	12769	151063	63325096
Decreased appetite	41.23	15.61	128	12735	250924	63225235
Neoplasm recurrence	38.93	15.61	16	12847	2622	63473537
Drug ineffective	38.71	15.61	98	12765	1044667	62431492
Disease progression	38.46	15.61	80	12783	122678	63353481
Radiation necrosis	38.14	15.61	10	12853	394	63475765
Neoplasm progression	36.73	15.61	41	12822	36387	63439772
Arthropathy	36.36	15.61	3	12860	234789	63241370
Peripheral swelling	34.80	15.61	6	12857	265936	63210223
Allergy test positive	33.90	15.61	10	12853	610	63475549
Disseminated intravascular coagulation	33.37	15.61	29	12834	19022	63457137
Rheumatoid arthritis	32.62	15.61	6	12857	253813	63222346
Enterocolitis	32.22	15.61	20	12843	7838	63468321
Tumour lysis syndrome	32.18	15.61	21	12842	8969	63467190
Central nervous system infection	31.95	15.61	10	12853	746	63475413
Left ventricular dilatation	31.47	15.61	9	12854	492	63475667
Systemic lupus erythematosus	31.45	15.61	3	12860	208915	63267244
Erythema	31.06	15.61	92	12771	175659	63300500
Constipation	30.91	15.61	108	12755	224835	63251324
Eastern Cooperative Oncology Group performance status worsened	30.71	15.61	11	12852	1243	63474916
Anorectal disorder	30.63	15.61	12	12851	1737	63474422
Cytokine release syndrome	29.64	15.61	24	12839	14290	63461869
Alanine aminotransferase increased	29.47	15.61	65	12798	103705	63372454
Brain abscess	28.41	15.61	12	12851	2106	63474053
Sinusitis	27.77	15.61	6	12857	226647	63249512
Drug intolerance	27.67	15.61	14	12849	308647	63167512
Hypokalaemia	27.22	15.61	63	12800	103741	63372418
Procedural vomiting	26.41	15.61	8	12855	535	63475624
Neurotoxicity	26.07	15.61	24	12839	16966	63459193
Hydrocephalus	25.63	15.61	15	12848	5285	63470874
Product dose omission issue	25.29	15.61	8	12855	234305	63241854
Abdominal discomfort	23.98	15.61	18	12845	320867	63155292
Malignant neoplasm progression	23.94	15.61	52	12811	82069	63394090
Klebsiella infection	23.54	15.61	17	12846	8549	63467610
Hyponatraemia	23.11	15.61	62	12801	111838	63364321
Gastrointestinal perforation	22.69	15.61	12	12851	3479	63472680
Arteriovenous malformation	22.66	15.61	9	12854	1351	63474808
Osteonecrosis of jaw	21.76	15.61	31	12832	35092	63441067
Small intestinal perforation	21.72	15.61	9	12854	1506	63474653
Large intestine perforation	21.43	15.61	16	12847	8466	63467693
Chemotherapy	21.36	15.61	9	12854	1570	63474589
Drug hypersensitivity	21.26	15.61	19	12844	310668	63165491
Hypocalcaemia	21.15	15.61	29	12834	31684	63444475
Arteritis	20.93	15.61	7	12856	645	63475514
Wound	20.66	15.61	4	12859	163259	63312900
Liver disorder	20.44	15.61	38	12825	53649	63422510
Pancytopenia	20.31	15.61	54	12809	96879	63379280
Stomatitis	20.25	15.61	68	12795	138657	63337502
Multiple organ dysfunction syndrome	20.16	15.61	39	12824	56713	63419446
Posterior reversible encephalopathy syndrome	20.07	15.61	21	12842	17324	63458835
Light chain analysis abnormal	19.73	15.61	5	12858	172	63475987
Sepsis	19.71	15.61	72	12791	153051	63323108
Ileus	19.17	15.61	19	12844	14706	63461453
Procedural nausea	19.09	15.61	7	12856	846	63475313
Cytopenia	19.00	15.61	17	12846	11584	63464575
Dermatitis acneiform	18.69	15.61	12	12851	4984	63471175
Respiratory failure	18.62	15.61	54	12809	101804	63374355
Aspartate aminotransferase increased	18.61	15.61	50	12813	90227	63385932
Blood phosphorus decreased	17.42	15.61	11	12852	4442	63471717
Leukopenia	17.15	15.61	44	12819	77246	63398913
Nasal dryness	17.13	15.61	11	12852	4570	63471589
Blood potassium abnormal	17.11	15.61	9	12854	2581	63473578
Musculoskeletal stiffness	17.10	15.61	8	12855	184610	63291549
Hypoalbuminaemia	16.81	15.61	16	12847	11789	63464370
Peritonitis	16.76	15.61	19	12844	17135	63459024
Seizure	16.76	15.61	62	12801	132572	63343587
Performance status decreased	16.72	15.61	10	12853	3668	63472491
Weight increased	16.61	15.61	17	12846	260775	63215384
Swelling	16.38	15.61	19	12844	275359	63200800
Myelopathy	16.37	15.61	9	12854	2817	63473342
Cerebral infarction	16.16	15.61	22	12841	23871	63452288
Hypoproteinaemia	16.09	15.61	8	12855	2041	63474118
Nausea	15.98	15.61	252	12611	854219	62621940
Septic shock	15.90	15.61	39	12824	66590	63409569

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Choroiditis	195.10	16.46	52	13005	1163	34942711
Endophthalmitis	190.24	16.46	65	12992	3443	34940431
Neutrophil count decreased	187.32	16.46	154	12903	50950	34892924
Intraocular pressure increased	149.30	16.46	61	12996	5322	34938552
Platelet count decreased	142.23	16.46	198	12859	119519	34824355
Febrile neutropenia	126.20	16.46	201	12856	136648	34807226
White blood cell count decreased	122.57	16.46	164	12893	95281	34848593
Myelosuppression	112.90	16.46	77	12980	19188	34924686
Interstitial lung disease	112.38	16.46	130	12927	65152	34878722
Uveitis	108.44	16.46	54	13003	7481	34936393
Eye pain	103.97	16.46	64	12993	13398	34930476
Visual acuity reduced	83.98	16.46	60	12997	16089	34927785
Decreased appetite	64.68	16.46	171	12886	166221	34777653
Disseminated intravascular coagulation	64.07	16.46	58	12999	21758	34922116
Neoplasm progression	58.92	16.46	57	13000	23243	34920631
Neutropenia	51.88	16.46	152	12905	156626	34787248
Pyrexia	51.66	16.46	253	12804	332760	34611114
Tumour lysis syndrome	51.36	16.46	46	13011	17013	34926861
Large intestine perforation	49.82	16.46	34	13023	8469	34935405
Hepatic function abnormal	47.54	16.46	70	12987	44293	34899581
Bone marrow failure	41.69	16.46	53	13004	29200	34914674
Hiccups	36.05	16.46	30	13027	10052	34933822
Hypoalbuminaemia	33.08	16.46	31	13026	12143	34931731
Strongyloidiasis	31.97	16.46	17	13040	2694	34941180
Stomatitis	30.52	16.46	56	13001	42458	34901416
Coombs positive haemolytic anaemia	30.35	16.46	12	13045	960	34942914
Off label use	27.24	16.46	257	12800	419267	34524607
Malignant neoplasm progression	26.82	16.46	83	12974	87963	34855911
Anaphylactic shock	26.13	16.46	31	13026	15910	34927964
Toxicity to various agents	26.01	16.46	22	13035	200340	34743534
Anaemia	25.80	16.46	162	12895	233173	34710701
Drug interaction	25.63	16.46	28	13029	225918	34717956
Capillary nail refill test abnormal	24.34	16.46	5	13052	33	34943841
Fall	24.29	16.46	24	13033	202861	34741013
Drug abuse	24.16	16.46	4	13053	99092	34844782
Gastrointestinal perforation	23.95	16.46	16	13041	3847	34940027
JC virus infection	23.68	16.46	13	13044	2195	34941679
Disease progression	23.43	16.46	91	12966	107986	34835888
Paronychia	23.29	16.46	15	13042	3390	34940484
Lymphadenitis	21.91	16.46	12	13045	2016	34941858
Myocardial infarction	21.75	16.46	9	13048	121076	34822798
Thrombocytopenia	21.49	16.46	115	12942	156132	34787742
Dermatitis acneiform	21.26	16.46	18	13039	6171	34937703
Hyperglycaemia	21.12	16.46	46	13011	39434	34904440
Tumour necrosis	20.83	16.46	10	13047	1278	34942596
Eye complication associated with device	20.68	16.46	3	13054	0	34943874
Lymphocyte count decreased	20.43	16.46	33	13024	22589	34921285
Septic shock	20.30	16.46	66	12991	71768	34872106
Blood lactate dehydrogenase increased	20.04	16.46	33	13024	22957	34920917
Immune effector cell-associated neurotoxicity syndrome	19.76	16.46	14	13043	3699	34940175
Hypokalaemia	19.72	16.46	57	13000	58157	34885717
Periodontitis	19.59	16.46	11	13046	1941	34941933
Pneumocystis jirovecii pneumonia	19.53	16.46	30	13027	19680	34924194
Pulmonary artery thrombosis	19.12	16.46	8	13049	740	34943134
Neuropathy peripheral	18.77	16.46	71	12986	83192	34860682
PaO2/FiO2 ratio decreased	18.00	16.46	4	13053	40	34943834
Uveitis-glaucoma-hyphaema syndrome	17.74	16.46	3	13054	5	34943869
Angle closure glaucoma	17.23	16.46	8	13049	949	34942925

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Neutrophil count decreased	379.97	14.50	274	23517	93685	79626912
Febrile neutropenia	307.53	14.50	361	23430	230638	79489959
Platelet count decreased	280.49	14.50	317	23474	194347	79526250
Myelosuppression	216.05	14.50	140	23651	40156	79680441
White blood cell count decreased	201.63	14.50	264	23527	188024	79532573
Interstitial lung disease	190.98	14.50	200	23591	112400	79608197
Choroiditis	190.40	14.50	50	23741	1331	79719266
Endophthalmitis	166.01	14.50	65	23726	6363	79714234
Bone marrow failure	132.82	14.50	115	23676	50992	79669605
Hepatic function abnormal	131.34	14.50	134	23657	72973	79647624
Intraocular pressure increased	124.78	14.50	59	23732	9146	79711451
Neutropenia	102.59	14.50	249	23542	287461	79433136
Pyrexia	95.15	14.50	427	23364	678282	79042315
Disseminated intravascular coagulation	93.81	14.50	81	23710	35761	79684836
Decreased appetite	93.22	14.50	268	23523	342150	79378447
Anaphylactic shock	89.49	14.50	79	23712	35917	79684680
Tumour lysis syndrome	83.56	14.50	64	23727	23875	79696722
Neoplasm progression	77.34	14.50	86	23705	51596	79669001
Uveitis	74.62	14.50	52	23739	16778	79703819
Pneumocystis jirovecii pneumonia	70.33	14.50	66	23725	32442	79688155
Visual acuity reduced	69.92	14.50	63	23728	29406	79691191
Anaemia	69.86	14.50	290	23501	444725	79275872
Large intestine perforation	69.29	14.50	47	23744	14520	79706077
Neuropathy peripheral	66.81	14.50	137	23654	141168	79579429
Eye pain	65.86	14.50	68	23723	37510	79683087
Malignant neoplasm progression	59.80	14.50	128	23663	135862	79584735
Joint swelling	56.91	14.50	9	23782	288637	79431960
Thrombocytopenia	55.81	14.50	190	23601	265069	79455528
Colony stimulating factor therapy	53.62	14.50	15	23776	509	79720088
Hypoalbuminaemia	51.45	14.50	46	23745	21251	79699346
Peripheral swelling	47.65	14.50	11	23780	269606	79450991
Disease progression	46.89	14.50	141	23650	184221	79536376
Strongyloidiasis	43.85	14.50	22	23769	3876	79716721
Acute lymphocytic leukaemia recurrent	42.64	14.50	23	23768	4701	79715896
Drug intolerance	42.46	14.50	13	23778	264106	79456491
Toxicity to various agents	42.45	14.50	38	23753	421502	79299095
Rheumatoid arthritis	42.23	14.50	6	23785	208464	79512133
Aortitis	41.61	14.50	16	23775	1491	79719106
Arthropathy	41.29	14.50	3	23788	177108	79543489
Fatigue	40.69	14.50	142	23649	929585	78791012
Enterocolitis	40.42	14.50	34	23757	14478	79706119
Hiccups	39.87	14.50	29	23762	10002	79710595
Gastrointestinal perforation	39.60	14.50	24	23767	6113	79714484
Fall	38.14	14.50	54	23737	487575	79233022
Septic shock	37.13	14.50	100	23691	122701	79597896
Stomatitis	37.08	14.50	112	23679	146645	79573952
Hypokalaemia	36.46	14.50	110	23681	143930	79576667
Constipation	36.41	14.50	174	23617	282876	79437721
Contraindicated product administered	35.79	14.50	3	23788	157535	79563062
Alanine aminotransferase increased	33.75	14.50	116	23675	162454	79558143
Overdose	33.58	14.50	7	23784	184199	79536398
Radiation necrosis	33.35	14.50	10	23781	435	79720162
Hyperglycaemia	32.98	14.50	68	23723	70267	79650330
Allergy test positive	32.39	14.50	11	23780	717	79719880
Drug abuse	32.21	14.50	5	23786	162686	79557911
Anorectal disorder	32.00	14.50	15	23776	2278	79718319
Coombs positive haemolytic anaemia	31.21	14.50	12	23779	1118	79719479
Neoplasm recurrence	31.17	14.50	18	23773	4196	79716401
Dermatitis acneiform	31.15	14.50	25	23766	9968	79710629
Arthralgia	30.95	14.50	79	23712	571724	79148873
Cytokine release syndrome	30.24	14.50	45	23746	35953	79684644
Periodontitis	30.09	14.50	18	23773	4478	79716119
Drug hypersensitivity	30.00	14.50	27	23764	298889	79421708
Small intestinal perforation	29.61	14.50	16	23775	3281	79717316
Confusional state	29.28	14.50	31	23760	317966	79402631
Musculoskeletal stiffness	29.25	14.50	8	23783	175000	79545597
Erythema	29.23	14.50	138	23653	223152	79497445
Sinusitis	29.02	14.50	11	23780	195490	79525107
Klebsiella infection	28.54	14.50	29	23762	15691	79704906
Tumour necrosis	28.15	14.50	13	23778	1909	79718688
Myocardial infarction	27.94	14.50	10	23781	184119	79536478
Pain	27.79	14.50	112	23679	703690	79016907
Paronychia	27.51	14.50	21	23770	7787	79712810
Cerebral infarction	27.36	14.50	49	23742	45627	79674970
Aspartate aminotransferase increased	27.11	14.50	97	23694	138544	79582053
Posterior reversible encephalopathy syndrome	26.73	14.50	36	23755	26245	79694352
Hypoproteinaemia	26.56	14.50	16	23775	4030	79716567
Peritonitis	26.40	14.50	37	23754	27999	79692598
Sepsis	25.97	14.50	153	23638	269275	79451322
Systemic lupus erythematosus	25.70	14.50	3	23788	121146	79599451
Central nervous system infection	25.58	14.50	11	23780	1366	79719231
Hypocalcaemia	25.47	14.50	50	23741	49874	79670723
Product dose omission issue	25.27	14.50	22	23769	247515	79473082
Hydrocephalus	25.09	14.50	21	23770	8879	79711718
Liver disorder	25	14.50	62	23729	72355	79648242
Neurotoxicity	24.98	14.50	39	23752	32479	79688118
Blood lactate dehydrogenase increased	24.73	14.50	43	23748	39127	79681470
Product use in unapproved indication	24.67	14.50	143	23648	250216	79470381
Cytopenia	23.97	14.50	30	23761	20353	79700244
Capillary nail refill test abnormal	23.80	14.50	5	23786	48	79720549
Off label use	23.80	14.50	391	23400	906824	78813773
Abdominal discomfort	23.57	14.50	24	23767	250703	79469894
Weight increased	23.41	14.50	29	23762	277357	79443240
Blood pressure decreased	23.34	14.50	74	23717	99392	79621205
Pulmonary artery thrombosis	22.23	14.50	10	23781	1382	79719215
Multiple organ dysfunction syndrome	21.71	14.50	82	23709	120164	79600433
Osteonecrosis of jaw	21.70	14.50	43	23748	43183	79677414
Eastern Cooperative Oncology Group performance status worsened	21.32	14.50	11	23780	2054	79718543
Light chain analysis abnormal	21.30	14.50	6	23785	209	79720388
Brain abscess	21.29	14.50	15	23776	4921	79715676
Drug interaction	21.20	14.50	59	23732	415124	79305473
Left ventricular dilatation	21.13	14.50	9	23782	1092	79719505
Drug ineffective for unapproved indication	21.10	14.50	47	23744	51191	79669406
Ileus	20.92	14.50	32	23759	26179	79694418
Memory impairment	20.87	14.50	4	23787	111730	79608867
Loss of personal independence in daily activities	20.65	14.50	3	23788	102577	79618020
Adrenal insufficiency	20.28	14.50	33	23758	28454	79692143
Peripheral sensory neuropathy	20.02	14.50	22	23769	13011	79707586
Chemotherapy	20.01	14.50	10	23781	1747	79718850
Wound	20.00	14.50	5	23786	116174	79604423
Myelopathy	19.80	14.50	14	23777	4619	79715978
Lymphadenitis	19.74	14.50	14	23777	4641	79715956
Respiratory failure	19.58	14.50	106	23685	180805	79539792
PaO2/FiO2 ratio decreased	19.48	14.50	4	23787	34	79720563
Bacteraemia	19.39	14.50	35	23756	32789	79687808
Gait disturbance	19.35	14.50	20	23771	207486	79513111
Pain in extremity	19.21	14.50	51	23740	364487	79356110
Arteritis	19.20	14.50	8	23783	919	79719678
Aspergillus infection	19.11	14.50	26	23765	19135	79701462
Swelling	18.98	14.50	22	23769	216689	79503908
Pneumonia bacterial	18.93	14.50	26	23765	19305	79701292
Anterior chamber flare	18.15	14.50	5	23786	160	79720437
Nasopharyngitis	18.00	14.50	30	23761	253851	79466746
Pancytopenia	17.85	14.50	97	23694	165648	79554949
Pneumonitis	17.82	14.50	49	23742	60811	79659786
Macular oedema	17.72	14.50	14	23777	5460	79715137
Dizziness	17.61	14.50	89	23702	526352	79194245
Child-Pugh-Turcotte score abnormal	17.46	14.50	3	23788	8	79720589
Arteriovenous malformation	17.10	14.50	9	23782	1752	79718845
Pneumonia	17.05	14.50	284	23507	659962	79060635
Weight decreased	17.01	14.50	52	23739	355146	79365451
Immune effector cell-associated neurotoxicity syndrome	16.90	14.50	14	23777	5834	79714763
Lymphocyte count decreased	16.86	14.50	41	23750	47248	79673349
Leukopenia	16.71	14.50	74	23717	116439	79604158
Drug ineffective	16.70	14.50	225	23566	1080688	78639909
Drug eruption	16.65	14.50	39	23752	43896	79676701
Intentional product misuse	16.57	14.50	4	23787	95161	79625436
Keratolysis exfoliativa acquired	16.34	14.50	3	23788	13	79720584
Drug-induced liver injury	16.25	14.50	50	23741	66067	79654530
Muscle spasms	16.11	14.50	17	23774	174713	79545884
Bronchopulmonary aspergillosis	16.11	14.50	26	23765	22268	79698329
Anaphylactic reaction	15.86	14.50	58	23733	83685	79636912
Cerebrovascular accident	15.60	14.50	14	23777	155278	79565319
Cytomegalovirus chorioretinitis	15.57	14.50	13	23778	5477	79715120
Headache	15.45	14.50	123	23668	653649	79066948
Cardiac failure congestive	15.33	14.50	12	23779	142390	79578207
Anxiety	15.29	14.50	32	23759	248480	79472117
Treatment failure	15.26	14.50	17	23774	170469	79550128
Vomiting	15.25	14.50	281	23510	665547	79055050
Hyponatraemia	15.23	14.50	98	23693	177750	79542847
Therapeutic product effect decreased	15.04	14.50	16	23775	163847	79556750
Cystitis haemorrhagic	15.00	14.50	16	23775	9156	79711441
Blood potassium abnormal	14.70	14.50	10	23781	3100	79717497

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
FDA MoA	N0000175450	Corticosteroid Hormone Receptor Agonists
FDA EPC	N0000175576	Corticosteroid
MeSH PA	D005938	Glucocorticoids
MeSH PA	D006728	Hormones
CHEBI has role	CHEBI:63562	glucocorticoid receptor agonists
MeSH PA	D000893	Anti-Inflammatory Agents
MeSH PA	D000932	Antiemetics
MeSH PA	D000970	Antineoplastic Agents
MeSH PA	D018931	Antineoplastic Agents, Hormonal
MeSH PA	D002491	Central Nervous System Agents
MeSH PA	D005765	Gastrointestinal Agents
MeSH PA	D018373	Peripheral Nervous System Agents
CHEBI has role	CHEBI:35472	anti-inflammatory drugs
CHEBI has role	CHEBI:35610	antineoplastic agents
CHEBI has role	CHEBI:35703	Xenobiotic
CHEBI has role	CHEBI:35705	immunosuppressive agents
CHEBI has role	CHEBI:37962	adrenergic agents
CHEBI has role	CHEBI:50919	antiemetico
CHEBI has role	CHEBI:78298	environmental contaminants

Drug Use | Suggest Off label Use Form| |View source of the data|

None

🐶 Veterinary Drug Use

Species	Use	Relation
Cats	Inflammation	Indication
Cattle	Primary bovine ketosis	Indication
Cattle	Inflammation	Indication
Dogs	Inflammation	Indication
Horses	Inflammation	Indication

🐶 Veterinary products

Product	Applicant	Ingredients
Dex-A-Vet Injection	Bimeda Animal Health Limited	1
Dex-A-Vet Injection	Bimeda Animal Health Limited	1
Dexamethasone Sodium Phosphate Inj.	Cronus Pharma Specialities India Private Limited	1
Dexium-SP	Bimeda Animal Health Limited	1

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	1.75	acidic
pKa2	6.8	acidic
pKa3	11.06	acidic
pKa4	13.94	acidic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Mechanism action	Bioact source	MoA source
Glucocorticoid receptor	Nuclear hormone receptor	P04150	GCR_HUMAN	AGONIST	IC50	9.30		CHEMBL	CHEMBL
Mineralocorticoid receptor	Nuclear hormone receptor	P08235	MCR_HUMAN		Ki	9.44		CHEMBL
Androgen receptor	Nuclear hormone receptor	P10275	ANDR_HUMAN		Ki	5.85		CHEMBL
Progesterone receptor	Nuclear hormone receptor	P06401	PRGR_HUMAN		Ki	6.25		CHEMBL
Androgen receptor	Transcription factor		ANDR_RAT		Ki	4.79		CHEMBL
Fatty acid-binding protein, liver	Unclassified		FABPL_RAT		Ki	4.66		CHEMBL
Progesterone receptor	Transcription factor		Q690N0_BOVIN		Ki	5.52		CHEMBL
Glucocorticoid receptor	Transcription factor		GCR_RAT		IC50	7.66		CHEMBL

External reference:

ID	Source
4020650	VUID
N0000148296	NUI
D00975	KEGG_DRUG
4017922	VANDF
4017923	VANDF
4020650	VANDF
C0770565	UMLSCUI
CHEBI:4462	CHEBI
CHEBI:41879	CHEBI
DEX	PDB_CHEM_ID
CHEMBL1201302	ChEMBL_ID
CHEMBL2021430	ChEMBL_ID
CHEMBL1200637	ChEMBL_ID
C004180	MESH_SUPPLEMENTAL_RECORD_UI
2BP70L44PR	UNII
9400	PUBCHEM_CID
DB01234	DRUGBANK_ID
227682	RXNORM
3245	MMSL
35380	MMSL
39663	MMSL
4552	MMSL
4554	MMSL
6848	MMSL
776	MMSL
d00206	MMSL
002174	NDDF
002176	NDDF
002177	NDDF
372584003	SNOMEDCT_US
396016009	SNOMEDCT_US
396017000	SNOMEDCT_US
7561000	SNOMEDCT_US
C0011777	UMLSCUI
CHEMBL1530428	ChEMBL_ID
CHEMBL384467	ChEMBL_ID
816	INN_ID
312-93-6	SECONDARY_CAS_RN
5743	PUBCHEM_CID
D003907	MESH_DESCRIPTOR_UI

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Dexamethasone Sodium Phosphate	HUMAN PRESCRIPTION DRUG LABEL	1	0404-9841	INJECTION, SOLUTION	4 mg	INTRA-ARTICULAR	ANDA	12 sections
Dexamethasone Sodium Phosphate	HUMAN PRESCRIPTION DRUG LABEL	1	0404-9841	INJECTION, SOLUTION	4 mg	INTRA-ARTICULAR	ANDA	12 sections
Dexamethasone Sodium Phosphate	HUMAN PRESCRIPTION DRUG LABEL	1	0404-9842	INJECTION, SOLUTION	10 mg	INTRAVENOUS	ANDA	11 sections
Dexamethasone Sodium Phosphate	HUMAN PRESCRIPTION DRUG LABEL	1	0404-9842	INJECTION, SOLUTION	10 mg	INTRAVENOUS	ANDA	11 sections
DEXAMETHASONE SODIUM PHOSPHATE	HUMAN PRESCRIPTION DRUG LABEL	1	0404-9843	INJECTION, SOLUTION	4 mg	INTRAVENOUS	ANDA	9 sections
DEXAMETHASONE SODIUM PHOSPHATE	HUMAN PRESCRIPTION DRUG LABEL	1	0404-9843	INJECTION, SOLUTION	4 mg	INTRAVENOUS	ANDA	9 sections
Dexamethasone Sodium Phosphate	HUMAN PRESCRIPTION DRUG LABEL	1	0641-0367	INJECTION	10 mg	INTRAMUSCULAR	ANDA	13 sections
Dexamethasone Sodium Phosphate	HUMAN PRESCRIPTION DRUG LABEL	1	0641-6145	INJECTION	4 mg	INTRA-ARTICULAR	ANDA	13 sections
Dexamethasone Sodium Phosphate	HUMAN PRESCRIPTION DRUG LABEL	1	0641-6146	INJECTION	4 mg	INTRA-ARTICULAR	ANDA	13 sections
Dexamethasone Sodium Phosphate	HUMAN PRESCRIPTION DRUG LABEL	1	11695-1411	SOLUTION/ DROPS	1 mg	OPHTHALMIC	ANDA	15 sections
Dexamethasone Sodium Phosphate	HUMAN PRESCRIPTION DRUG LABEL	1	16590-068	SOLUTION/ DROPS	1 mg	OPHTHALMIC	ANDA	11 sections
Dexamethasone Sodium Phosphate	HUMAN PRESCRIPTION DRUG LABEL	1	21695-847	SOLUTION	1 mg	OPHTHALMIC	ANDA	18 sections
Dexamethasone Sodium Phosphate	HUMAN PRESCRIPTION DRUG LABEL	1	24208-720	SOLUTION/ DROPS	1 mg	OPHTHALMIC	ANDA	16 sections
Dexamethasone Sodium Phosphate	HUMAN PRESCRIPTION DRUG LABEL	1	24208-720	SOLUTION/ DROPS	1 mg	OPHTHALMIC	ANDA	16 sections
Dexamethasone Sodium Phosphate	HUMAN PRESCRIPTION DRUG LABEL	1	42254-088	SOLUTION/ DROPS	1 mg	OPHTHALMIC	ANDA	15 sections
Dexamethasone Sodium Phosphate	Human Prescription Drug Label	1	50090-0627	INJECTION, SOLUTION	4 mg	INTRAMUSCULAR	ANDA	12 sections
Dexamethasone Sodium Phosphate	HUMAN PRESCRIPTION DRUG LABEL	1	50090-1922	INJECTION, SOLUTION	4 mg	INTRA-ARTICULAR	ANDA	13 sections
Dexamethasone Sodium Phosphate	HUMAN PRESCRIPTION DRUG LABEL	1	50090-2313	INJECTION, SOLUTION	4 mg	INTRA-ARTICULAR	ANDA	13 sections
Dexamethasone Sodium Phosphate	HUMAN PRESCRIPTION DRUG LABEL	1	50090-2313	INJECTION, SOLUTION	4 mg	INTRA-ARTICULAR	ANDA	13 sections
Dexamethasone Sodium Phosphate	HUMAN PRESCRIPTION DRUG LABEL	1	50090-2313	INJECTION, SOLUTION	4 mg	INTRA-ARTICULAR	ANDA	13 sections
DEXAMETHASONE SODIUM PHOSPHATE	Human Prescription Drug Label	1	50090-3300	INJECTION, SOLUTION	4 mg	INTRAVENOUS	ANDA	10 sections
DEXAMETHASONE SODIUM PHOSPHATE	Human Prescription Drug Label	1	50090-3300	INJECTION, SOLUTION	4 mg	INTRAVENOUS	ANDA	10 sections
Dexamethasone Sodium Phosphate	HUMAN PRESCRIPTION DRUG LABEL	1	50090-3541	INJECTION	10 mg	INTRAMUSCULAR	ANDA	12 sections
Dexamethasone Sodium Phosphate	HUMAN PRESCRIPTION DRUG LABEL	1	50090-3541	INJECTION	10 mg	INTRAMUSCULAR	ANDA	12 sections
Dexamethasone Sodium Phosphate	HUMAN PRESCRIPTION DRUG LABEL	1	50090-4567	INJECTION, SOLUTION	10 mg	INTRAVENOUS	ANDA	9 sections
DEXAMETHASONE SODIUM PHOSPHATE	HUMAN PRESCRIPTION DRUG LABEL	1	51662-1297	INJECTION	4 mg	SOFT TISSUE	ANDA	10 sections
DEXAMETHASONE SODIUM PHOSPHATE	HUMAN PRESCRIPTION DRUG LABEL	1	51662-1343	INJECTION	10 mg	INTRAMUSCULAR	ANDA	10 sections
DEXAMETHASONE SODIUM PHOSPHATE	HUMAN PRESCRIPTION DRUG LABEL	1	51662-1343	INJECTION	10 mg	INTRAMUSCULAR	ANDA	10 sections
DEXAMETHASONE SODIUM PHOSPHATE	HUMAN PRESCRIPTION DRUG LABEL	1	51662-1370	INJECTION, SOLUTION	4 mg	INTRAMUSCULAR	ANDA	13 sections
DEXAMETHASONE SODIUM PHOSPHATE	HUMAN PRESCRIPTION DRUG LABEL	1	51662-1370	INJECTION, SOLUTION	4 mg	INTRAMUSCULAR	ANDA	13 sections